Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: Why keep patients doing their best?

Arthritis Care and Research

Volumn 67, Issue 6, 2015, Pages 739-745

  Markusse, Iris M ^a   Dirven, Linda ^a   Han, K Huub ^b   Ronday, H Karel ^c   Kerstens, Pit J S M ^d   Lems, Willem F ^e   Huizinga, Tom W J ^a   Allaart, Cornelia F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d Reade   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE CONTROL; FEMALE; FOLLOW UP; HUMAN; LEARNING; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MIDDLE AGED; MOTIVATION; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT DROPOUTS; PATIENT PARTICIPATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; AGE; ARTHRITIS, RHEUMATOID; ATTITUDE TO HEALTH; CLINICAL TRIAL; DISEASE COURSE; MEDICATION COMPLIANCE; NETHERLANDS; PATIENT; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; NETHERLANDS; PATIENT DROPOUTS; PATIENTS; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929924632     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22540     Document Type: Article

References (23)

1. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, et al., Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013; 14: 72-80.
2. Blazek S, Holzhey D, Jungert C, Borger MA, Fuernau G, Desch S, et al., Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC Cardiovasc Interv 2013; 6: 20-6.
3. Engh CA Jr, Hopper RH Jr, Huynh C, Ho H, Sritulanondha S, Engh CA Sr., A prospective, randomized study of cross-linked and non-cross-linked polyethylene for total hip arthroplasty at 10-year follow-up. J Arthroplasty 2012; 27 Suppl 8: 2-7.
4. Beaupre L, Secretan C, Johnston DW, Lavoie G., A randomized controlled trial comparing patellar retention versus patellar resurfacing in primary total knee arthroplasty: 5-10 year follow-up. BMC Res Notes 2012; 5: 273.
5. Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J, et al., Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology 2012; 56: 516-22.
6. Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH, and the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators. Association between immediate initiation of intramuscular interferon β-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69: 183-90.
7. Heliovaara-Peippo S, Oksjoki R, Halmesmaki K, Kaaja R, Teperi J, Grenman S, et al., The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: a 10-year follow-up of a randomised trial. Maturitas 2011; 69: 354-8.
8. Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, et al., Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol 2012; 82: 524-31.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
10. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
11. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al., Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
12. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Rheumatology (Oxford) 1996; 35: 1101-5.
13. Siegert CE, Vleming LJ, Vandenbroucke JP, Cats A., Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984; 3: 305-9.
14. Van der Heijde D,. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26: 743-5.
15. Udrea G, Dumitrescu B, Purcarea M, Balan I, Rezus E, Deculescu D., Patients' perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis. J Med Life 2009; 2: 227-31.
16. Lee SJ, Lenert L, Weisman S, Kavanaugh A., Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials. J Rheumatol 2005; 32: 2317-25.
17. Reisine S, Fifield J, Winkelman DK., Characteristics of rheumatoid arthritis patients: who participates in long-term research and who drops out? Arthritis Care Res 2000; 13: 3-10.
18. Jenkins V, Fallowfield L., Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 2000; 82: 1783-8.
19. McCann SK, Campbell MK, Entwistle VA., Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials 2010; 11: 31.
20. Costenbader KH, Brome D, Blanch D, Gall V, Karlson E, Liang MH., Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study. Arthritis Rheum 2007; 57: 49-55.
21. Strusberg I, Bertoli AM, Ramos M, Fierro G, Pizzolato R, Exeni I, et al., Factors associated with patients' loss to follow-up after finishing randomized clinical trial participation. Contemp Clin Trials 2005; 26: 38-44.
22. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Jarvenpaa S, Leirisalo-Repo M, et al., The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Rheum 2009; 60: 1222-31.
23. Van Tuyl LH, Boers M, Lems WF, Landewe RB, Han H, van der Linden S, et al., Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010; 69: 807-12.